This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/033834-2023

Tender

Tender for the Supply of Services - Independent Central Review Of Primary Outcome Data For The GLO-BHNL Platform Clinical Trial - University Of Birmingham

THE UNIVERSITY OF BIRMINGHAM

F02: Contract notice

Notice identifier: 2023/S 000-033834

Procurement identifier (OCID): ocds-h6vhtk-041a2f

Published 15 November 2023, 5:00pm

Section I: Contracting authority

I.1) Name and addresses

THE UNIVERSITY OF BIRMINGHAM

Edgbaston

BIRMINGHAM

B152TT

Contact

Kseniya Samsonik

Email

K.Samsonik@bham.ac.uk

Country

United Kingdom

Region code

UKG31 - Birmingham

Companies House

RC000645

Internet address(es)

Main address

https://www.birmingham.ac.uk/

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

www.in-tendhost.co.uk/universityofbirmingham/aspx/Home

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

www.in-tendhost.co.uk/universityofbirmingham/aspx/Home

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Education

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Tender for the Supply of Services - Independent Central Review Of Primary Outcome Data For The GLO-BHNL Platform Clinical Trial - University Of Birmingham Reference number

SC12106/23

II.1.2) Main CPV code

• 85150000 - Medical imaging services

II.1.3) Type of contract

Services

II.1.4) Short description

The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.

Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.

Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.

Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.

This project may be funded by the European Regional Development Fund (ERDF) or;

- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.

Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.

II.1.5) Estimated total value

Value excluding VAT: £5,000,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS codes

• UKG3 - West Midlands

II.2.4) Description of the procurement

The University of Birmingham invites tenders for independent central review of the primary outcome data for the clinical platform trial, Glo-BNHL. The platform aims to test a wide range of therapies over its lifetime in order to find better treatments for the rare paediatric cancer, B-cell non-Hodgkin's Lymphoma. The design allows addition of new treatment arms as novel therapies become available for testing. There are currently 2 treatment arms.

Independent central review of the clinical data that informs the primary outcome measures is required, to include: cross sectional imaging by CT or MRI, PET-CT scan, bone marrow aspirate, bone marrow trephine and lumbar puncture pathology reports.

Glo-BNHL is an international trial with participating sites in the UK, Europe, USA, Canada, Australia, New Zealand and Israel. A total of 45 sites will participate, with international sites' activity coordinated by 15 National Coordinating Centres.

Glo-BNHL recently received ethics approval in the UK and will open later this year. Approval in the other participating nations will follow. An expedient solution to independent central review is therefore required.

This project may be funded by the European Regional Development Fund (ERDF) or;

- European Structural and Investment Fund (ESIF) or;
- Research Councils UK (RCUK), the strategic partnership of the UK's seven Research Councils.

Please refer to Appendix A via www.in-tendhost.co.uk/universityofbirmingham/aspx/Home for full specification of requirements.

II.2.5) Award criteria

Quality criterion - Name: Compliance to the Specifications / Weighting: 45

Quality criterion - Name: After Sales and Technical back up / Weighting: 15

Quality criterion - Name: Delivery and Training / Weighting: 15

Quality criterion - Name: Sustainability and Environmental / Weighting: 10

Quality criterion - Name: Standard Supplier Questionnaire (SQ) Part 1 and Part 2 /

Weighting: 10

Price - Weighting: 5

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

30 March 2024

End date

30 March 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

15 December 2023

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.7) Conditions for opening of tenders

Date

15 December 2023

Local time

12:01pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

University of Birmingham

Birmingham

Country

United Kingdom